More on RCUS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (8.0 Score)
- Holders

Upcoming Events

- Earnings (7/31/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcus Biosciences (NY:RCUS)
Delayed: 22.11 -0.1 (0.45%)
Prev. Close $22.21  
Open$21.79 
52 Wk High$ 
52 Wk Low$ 
Day High$22.36 
Day Low$21.34 
P/E N/A  
EPS$ 
Volume653,865 


Mar 2, 2026 06:26 AM Arcus Biosciences (RCUS) PT Raised to $49 at Leerink Partners
Feb 26, 2026 04:05 PM Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Feb 25, 2026 04:40 PM Form S-3ASR Arcus Biosciences, Inc.
Feb 25, 2026 04:21 PM Form S-8 Arcus Biosciences, Inc.
Feb 25, 2026 04:12 PM Form 10-K Arcus Biosciences, Inc. For: Dec 31
Feb 25, 2026 04:09 PM Form 8-K Arcus Biosciences, Inc. For: Feb 25
Feb 25, 2026 04:09 PM Arcus Biosciences (RCUS) Tops Q4 EPS by 21c
Feb 25, 2026 04:05 PM Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Feb 23, 2026 05:00 PM Arcus presents kidney cancer drug data showing extended survival
Feb 23, 2026 05:00 PM Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
View All Articles

Entities mentioned with RCUS

View All Entities